title: Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
abstract: OBJECTIVE
  To assess the effect of ergot derivatives on cardiac valves in patients with Parkinson's disease (PD).
  
  
  METHODS
  Echocardiography was performed on 46 PD patients who used either pergolide or cabergoline (MonoPD) or both (MixPD) for a minimum of 1 year and 49 age-matched healthy controls. Valvular regurgitation was graded as mild, moderate and severe. MonoPD and MixPD groups were compared with regard to demographic features, drug profile and valvulopathy.
  
  
  RESULTS
  The PD group had a mean age of 63 years, agonist duration of 3.8 years and agonist equivalent dose of 3.5mg/day. Moderate regurgitation in all three valves was significantly more common in the PD group than the controls. Severe valvular regurgitation was not observed in either group, with the exception of one PD patient. The frequency of valvulopathy and doses of agonists did not differ between MixPD and MonoPD groups.
  
  
  CONCLUSIONS
  PD patients on dopamine ergot agonists are prone to moderate valvular regurgitation more than age-matched controls. However, the frequency of valvulopathy was similar in patients who used either one or more agonists.
authors.affiliation: Department of Neurology, Education and Research Hospital of Sisli Etfal, 34360 Istanbul, Turkey.
authors.forename: Gülay
authors.initials: G
authors.lastname: Kenangil
authors.forename: Sibel
authors.initials: S
authors.lastname: Ozekmekçi
authors.forename: Lale
authors.initials: L
authors.lastname: Koldas
authors.forename: Taylan
authors.initials: T
authors.lastname: Sahin
authors.forename: Ethem
authors.initials: E
authors.lastname: Erginöz
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001022:Aortic Valve Insufficiency / Q000139:chemically induced / Q000175:diagnosis; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004452:Echocardiography / Q000187:drug effects; D004873:Ergolines / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D014262:Tricuspid Valve Insufficiency / Q000139:chemically induced / Q000175:diagnosis
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D004873:Ergolines; D010479:Pergolide; D000077465:Cabergoline